Advertisement

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

      Highlights

      • The incidence of delayed irAEs >12 months after commencing anti-PD-1 was 5.3%.
      • Delayed irAEs occurred in 118 patients; these were often high grade (39% G3+) including two delayed irAE-related deaths.
      • Delayed irAEs were often difficult to manage; 68% required steroids and 23% required an additional immunosuppressive agent.
      • Most occurred during anti-PD-1 therapy (74%), but delayed irAEs were also reported up to 26 months after stopping anti-PD-1.

      Background

      Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)], but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature and management of delayed irAEs in patients receiving anti-PD-1-based immunotherapy.

      Patients and methods

      Patients with delayed irAEs from 20 centres were studied. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD-1-based therapy and surviving >1 year. Onset, clinical features, management and outcomes of irAEs were examined.

      Results

      One hundred and eighteen patients developed a total of 140 delayed irAEs (20 after initial combination with anti-CTLA4), with an estimated incidence of 5.3% (95% confidence interval 4.0-6.9, 53/999 patients at sites with available data). The median onset of delayed irAE was 16 months (range 12-53 months). Eighty-seven patients (74%) were on anti-PD-1 at irAE onset, 15 patients (12%) were <3 months from the last dose and 16 patients (14%) were >3 months from the last dose of anti-PD-1. The most common delayed irAEs were colitis, rash and pneumonitis; 55 of all irAEs (39%) were ≥grade 3. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive agent in 27 patients (23%). There were two irAE-related deaths: encephalitis with onset during anti-PD-1 and a multiple-organ irAE with onset 11 months after ceasing anti-PD-1. Early irAEs (<12 months) had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%).

      Conclusions

      Delayed irAEs occur in a small but relevant subset of patients. Delayed irAEs are often different from previous irAEs, may be high grade and can lead to death. They mostly occur in patients still receiving anti-PD-1. The risk of delayed irAE should be considered when deciding the duration of treatment in responding patients. However, patients who stop treatment may also rarely develop delayed irAE.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ESMO Member Login

      Full access to the journal is a member benefit for ESMO Members, Login via the ESMO website to access all journal content.

      Subscribe:

      Subscribe to Annals of Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Haanen J.B.A.G.
        • Carbonnel F.
        • Robert C.
        • et al.
        Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†.
        Ann Oncol. 2017; 28: iv119-iv142
        • Weber J.S.
        • Hodi F.S.
        • Wolchok J.D.
        • et al.
        Safety profile of Nivolumab Monotherapy: a pooled analysis of patients with advanced melanoma.
        J Clin Oncol. 2017; 35: 785-792
        • Topalian S.L.
        • Sznol M.
        • McDermott D.F.
        • et al.
        Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab.
        J Clin Oncol. 2014; 32: 1020-1030
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.
        N Engl J Med. 2019; 381: 1535-1546
        • Nardin C.
        • Dalle S.
        • Leccia M.T.
        • et al.
        Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).
        J Clin Oncol. 2020; 38: 10057
        • Couey M.A.
        • Bryan Bell R.
        • Patel A.A.
        • et al.
        Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.
        J Immunother Cancer. 2019; 7: 165
        • Johnson D.B.
        • McDonnell W.J.
        • Gonzalez-Ericsson P.I.
        • et al.
        A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
        Nat Med. 2019; 25: 1243-1250
        • Braaten T.J.
        • Brahmer J.R.
        • Forde P.M.
        • et al.
        Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
        Ann Rheum Dis. 2020; 79: 332-338
        • Robert C.
        • Ribas A.
        • Schachter J.
        • et al.
        Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
        Lancet Oncol. 2019; 20: 1239-1251
        • Hamid O.
        • Robert C.
        • Daud A.
        • et al.
        Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
        Ann Oncol. 2019; 30: 582-588
        • Robert C.
        • Ribas A.
        • Hamid O.
        • et al.
        Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.
        J Clin Oncol. 2018; 36: 1668-1674
        • Jansen Y.J.L.
        • Rozeman E.A.
        • Mason R.
        • et al.
        Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
        Ann Oncol. 2019; 30: 1154-1161
        • Warner A.B.
        • Palmer J.S.
        • Shoushtari A.N.
        • et al.
        Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade.
        J Clin Oncol. 2020; 38: 1655-1663
        • Tan A.C.
        • Emmett L.
        • Lo S.
        • et al.
        FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
        Ann Oncol. 2018; 29: 2115-2120
        • Rozeman E.A.
        • Menzies A.M.
        • van Akkooi A.C.J.
        • et al.
        Identification of the optimal combination dosing schedule of neoadjuvant Ipilimumab plus Nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
        Lancet Oncol. 2019; 20: 948-960
        • Johnson D.B.
        • Reynolds K.L.
        • Sullivan R.J.
        • et al.
        Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
        Lancet Oncol. 2020; 21: e398-e404